Impact of urine cyclic AMP relative to plasma arginine vasopressin on response to tolvaptan in patients with chronic kidney disease and heart failure

[1]  T. Imamura,et al.  Prognostic impact of urine cyclic AMP levels in patients with chronic kidney disease , 2022, Clinical and Experimental Nephrology.

[2]  T. Imamura,et al.  Altered arginine vasopressin-cyclic AMP-aquaporin 2 pathway in patients with chronic kidney disease , 2022, Clinical and Experimental Nephrology.

[3]  N. Hirawa,et al.  Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial , 2022, Clinical and Experimental Nephrology.

[4]  S. Sasaki,et al.  Updates and Perspectives on Aquaporin-2 and Water Balance Disorders , 2021, International journal of molecular sciences.

[5]  T. Imamura,et al.  Expression of aquaporin-2 in the collecting duct and responses to tolvaptan , 2020, CEN Case Reports.

[6]  A. Tanaka,et al.  Efficacy of Long‐Term Treatment With Tolvaptan to Prolong the Time Until Dialysis Initiation in Patients With Chronic Kidney Disease and Heart Failure , 2019, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[7]  N. Sato,et al.  Real-World Effectiveness and Tolerability of Tolvaptan in Patients With Heart Failure　- Final Results of the Samsca Post-Marketing Surveillance in Heart Failure (SMILE) Study. , 2019, Circulation journal : official journal of the Japanese Circulation Society.

[8]  O. Saito,et al.  Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients , 2019, International Urology and Nephrology.

[9]  N. Sato,et al.  Effects of Tolvaptan on Volume Overload in Patients with Heart Failure. , 2018, International heart journal.

[10]  W. Shimizu,et al.  Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria , 2017, Heart and Vessels.

[11]  Y. Toya,et al.  Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure , 2017, Clinical and Experimental Nephrology.

[12]  H. Rakugi,et al.  Urine Osmolarity Predicts the Body Weight-Reduction Response to Tolvaptan in Chronic Kidney Disease Patients: A Retrospective, Observational Study , 2015, Nephron.

[13]  T. Imamura,et al.  Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[14]  T. Imamura,et al.  Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[15]  T. Lauridsen,et al.  Abnormal function of the vasopressin-cyclic-AMP-aquaporin2 axis during urine concentrating and diluting in patients with reduced renal function. A case control study , 2010, BMC nephrology.

[16]  Yasuhiko Tomino,et al.  Revised equations for estimated GFR from serum creatinine in Japan. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  K. Swedberg,et al.  Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.

[18]  C. Wilcox.  New insights into diuretic use in patients with chronic renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[19]  T. Zenser,et al.  Evaluation of renal concentrating and diluting ability. , 1993, Clinics in laboratory medicine.

[20]  A. Broadus,et al.  Nephrogenous cyclic adenosine monophosphate as a parathyroid function test. , 1977, The Journal of clinical investigation.

[21]  Y. Shibagaki,et al.  Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment　- Results From the K-STAR Study. , 2017, Circulation journal : official journal of the Japanese Circulation Society.

[22]  Tsukasa Nakamura,et al.  Effect of tolvaptan in patients with chronic kidney disease due to diabetic nephropathy with heart failure. , 2014, International heart journal.